.jpg "LivaNova PLC (NASDAQ: LIVN)")
In a report issued on September 6, Scott Bardo from Berenberg Bank maintained a Buy rating on LivaNova PLC (LIVN), with a price target of $114. The company’s shares closed last Monday at $80.53.
Bardo has an average return of 28.6% when recommending LivaNova PLC.
According to TipRanks.com, Bardo is ranked #559 out of 5535 analysts.
Currently, the analyst consensus on LivaNova PLC is a Strong Buy with an average price target of $98.33, which is a 26.1% upside from current levels. In a report issued on September 6, Piper Jaffray also maintained a Buy rating on the stock with a $90 price target.
See today’s analyst top recommended stocks >>
Based on LivaNova PLC’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $29.22 million. In comparison, last year the company had a net profit of $15.28 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others.
